ARTICLE | Clinical News
NeoTherapeutics Phase IIb extension
April 6, 2000 7:00 AM UTC
NEOT began an open-label extension of its ongoing U.S. Phase IIb trial of Neotrofin AIT-082 leteprinim to treat mild to moderate Alzheimer's disease. The extension allows patients who complete the tri...